Enterome Announces First Patient In Phase 1/2 Trial With Second OncoMimics ™ Vaccine, EO2463, In Non-Hodgkin Lymphoma
PARIS, July 12, 2021 / PRNewswire / – ENTEROME SA, a clinical-stage biopharmaceutical company developing new drugs based on its unique ability to decode molecular interactions in the gut microbiome impacting human health, announces first patient has been assayed in a phase 1/2 clinical trial (‘SIDNEY’) with EO2463, his second OncoMimicsMT vaccine for the treatment of indolent non-Hodgkin lymphoma (NHL). The first clinical data from the trial are expected in 2022.
EO2463 is an innovative, ready-to-use, microbiome peptide-based cancer vaccine that combines four microbiome peptides of lineage markers specific to B cells. EO2463 is designed to induce the immune system to recognize B cells as bacterial (i.e. (i.e. non-self) and trigger a targeted cell killing response. The clinical rationale for targeting these lineage-specific cell markers is to induce complete depletion of the malignant B lymphocytes that cause NHL.
The SIDNEY trial (EONHL1-20; NCT04669171) is a multicenter, open-label, phase 1/2 study evaluating the safety, tolerability, immunogenicity and preliminary efficacy of EO2463 as monotherapy and in combination with lenalidomide and / or the standard lenalidomide. rituximab in patients with follicular and marginal zone lymphoma. A total of 60 patients should be included in Europe and the United States.
This is the third clinical trial involving OncoMimicsMT candidate vaccines against cancer in solid and liquid malignancies will be launched by Enterome within the last 12 months.
Professor Pier Luigi Zinzani, MD, PhD, University of Bologna (Italy), is the global coordinating researcher of SIDNEY. Professor Zinzani is a renowned hematologist with extensive experience in clinical research and drug development in the field of NHL, Hodgkin’s disease and chronic lymphocytic leukemia.
Professor Zinzani, mentionned: “Targeting specific B cell antigens with a non-stand-alone, ready-to-use therapeutic vaccine is a very interesting approach to treating NHL. We are excited to begin clinical studies to determine whether EO2463 may impact not only disease relapse in combination with established standard care options, but also very early stages of NHL when used in monotherapy. We look forward to seeing the immunological and clinical impact of the vaccine and to providing updates on the progress of this study. “
Dr. Jan Fagerberg, Chief Medical Officer of Enterome, said: “EO2463 is the second Enterome microbiome-peptide-based cancer vaccine generated from our unique drug discovery platform. This clinical trial is another important step in our strategy to provide proof of concept data for our OncoMimicsMT vaccines, which we believe can target both solid and liquid malignant tumors. We are excited to launch this trial and believe that the data we expect to generate from clinical trials with EO2401 and EO2463 will position Enterome as a clear leader in next-generation cancer vaccines. “
External Communication and Investor Relations Manager
Sylvie Berrebi / Mark Swallow / David Dible
Phone. +44 (0) 7714 306525
Enterome is a clinical-stage biopharmaceutical company developing new drugs based on its unique ability to decode molecular interactions in the gut microbiome impacting human health. Enterome’s success is based on its unique ability to identify small proteins and peptides (“effectors”) from intestinal bacteria that may provide therapeutic benefit in humans.
Enterome leverages this unique ability to develop two very promising pipelines of clinical and preclinical candidates focused on cancer, inflammatory and metabolic diseases:
– OncoMimics: innovative, ready-to-use cancer vaccines powered by a microbiome-peptide (EO2401, EO2463). EO2401 is in phase 1/2 clinical trials in patients with glioblastoma and adrenal tumors. EO2463 is in a phase 1/2 clinical trial for indolent B-cell non-Hodgkin lymphoma.
– EndoMimics: a new generation of biological products targeting inflammatory diseases (EM101) and metabolic diseases.
These pipelines were created using Enterome’s proprietary, highly efficient drug discovery platform that uses machine learning and laboratory tests to query and decode the world’s largest database of bacterial proteins. intestinal tract, a unique source of new precision drugs.
In addition, Enterome’s clinical candidate, Sibofimloc (also known as TAK-018), is advancing in phase 2 clinical trials in Crohn’s disease. Sibofimloc is a Takeda partner worldwide, with Enterome retaining a significant share of profits in the United States.
Enterome is headquartered at Paris, France) and is backed by major venture capitalists.
For more information, please visit the company’s website at: www.enterome.com